Navigation Links
ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
Date:8/5/2008

HALIFAX, Aug. 5 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, today announced receipt of patent approval from the Japanese Patent Office for its vaccine platform. The specific patent, Vaccines with enhanced immune response and methods for their preparation, claims broad exclusivity that an effective, long-term immune response to treat a disease can be produced using a vaccine comprising of an antigen, an adjuvant, vesicles known as liposomes, and a hydrophobic carrier.

"We have a novel technology that enhances vaccines dramatically, so receiving patent approval is important in protecting our competitive advantage," commented Dr. Marc Mansour, Vice President R&D at IVT.

Securing broad patent coverage is part of IVT's strategy to maximize the market potential of its VacciMax(R) platform in the largest pharmaceutical markets in the world; including the US, Europe, Canada, Australia and Japan. The company's VacciMax(R) technology is based on a novel approach to the use of liposomes in an oil emulsion. IVT has discovered that liposomes, stabilized in the VacciMax(R) technology, significantly enhance antibody production, creating a more rapid immune response, following a single vaccination. The responses are also long lasting, without requiring booster immunizations.

"The issuance of the patent in Japan complements the US and European patents for our vaccine platform technology," said Dr Randal Chase, President and CEO of IVT. "We are watching the growth of the Asian market, and patent coverage in Japan is an important step in contributing to the wide reach of our vaccine products."

About IVT

ImmunoVaccine Technologies Inc. is a private, clinical-stage, vaccine development company. Through its own biotech research, patented VacciMax(R) and DepoVax(TM) technologies, and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world.

In December 2007, IVT signed a binding MOU to acquire Pennsylvania-based Immunotope Inc. The acquisition enables IVT to create an entire pipeline of proprietary therapeutic cancer and infectious-disease specific vaccines. In January 2008, IVT licensed its technology to Pfizer Animal health, marking a pivotal step in achieving its vision of delivering breakthrough vaccines.

http://www.immunovaccine.com


'/>"/>
SOURCE ImmunoVaccine Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
2. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
3. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
4. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
5. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
6. MaxWell Biocorporation, LLC, and International Medical Information Technologies, Inc., Announce Partnership
7. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
8. [video] Edward Spink, CEO of TurboSonic Technologies, Inc. Discusses Contract With Biofuel Producer in Exclusive Interview on WallSt.nets 3-Minute Press Show
9. Local officials move toward monitoring nanotechnologies
10. VNUS Medical Technologies to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
11. China Medical Technologies Adjusts Conversion Rate of Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):